

This is a self-archived version of an original article. This version may differ from the original in pagination and typographic details.

Author(s): Haataja, Tatu J.K.; Capoulade, Romain; Lecointe, Simon; Hellman, Maarit; Merot, Jean; Permi, Perttu; Pentikäinen, Ulla

Title: Critical Structural Defects Explain Filamin A Mutations Causing Mitral Valve Dysplasia

Year: 2019

Version: Accepted version (Final draft)

Copyright: © 2019 Biophysical Society.

Rights: In Copyright

Rights url: <http://rightsstatements.org/page/InC/1.0/?language=en>


Please cite the original version:

Haataja, T. J., Capoulade, R., Lecointe, S., Hellman, M., Merot, J., Permi, P., & Pentikäinen, U. (2019). Critical Structural Defects Explain Filamin A Mutations Causing Mitral Valve Dysplasia. *Biophysical Journal*, 117(8), 1467-1475. <https://doi.org/10.1016/j.bpj.2019.08.032>

Journal Pre-proof

Critical Structural Defects Explain Filamin A Mutations Causing Mitral Valve Dysplasia

Tatu J.K. Haataja, Romain Capoulade, Simon Lecointe, Maairt Hellman, Jean Merot, Perttu Permi, Ulla Pentikäinen



PII: S0006-3495(19)30749-0

DOI: <https://doi.org/10.1016/j.bpj.2019.08.032>

Reference: BPJ 9839

To appear in: *Biophysical Journal*

Received Date: 7 June 2019

Accepted Date: 28 August 2019

Please cite this article as: Haataja TJK, Capoulade R, Lecointe S, Hellman M, Merot J, Permi P, Pentikäinen U, Critical Structural Defects Explain Filamin A Mutations Causing Mitral Valve Dysplasia, *Biophysical Journal* (2019), doi: <https://doi.org/10.1016/j.bpj.2019.08.032>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2019 Biophysical Society.

Critical Structural Defects Explain Filamin A Mutations Causing Mitral Valve Dysplasia

**Tatu J.K. Haataja, Romain Capoulade, Simon Lecointe, Maairt Hellman, Jean Merot,
Perttu Permi & Ulla Pentikäinen***

¹Department of Biological and Environmental Science and Nanoscience Center, University of Jyväskylä, 40014 Jyväskylä, Finland

²l'institut du thorax, INSERM, CNRS, UNIV Nantes, Nantes, France

³Department of Chemistry and Nanoscience Center, University of Jyväskylä, 40014 Jyväskylä, Finland

⁴Institute of Biomedicine, University of Turku, 20520 Turku, Finland;

⁵Turku Bioscience Centre, University of Turku, 20520 Turku, Finland

*To whom correspondence should be addressed: Ulla Pentikäinen, Institute of Biomedicine, University of Turku, 20520 Turku, Finland; ulla.pentikainen@utu.fi; Tel: +358 (0)50 5012 574

ABSTRACT

Mitral valve diseases affect approximately 3% of the population and are the most common reasons for valvular surgery because no drug-based treatments exist. Inheritable genetic mutations have now been established as the cause of mitral valve insufficiency, and four different missense mutations in the filamin A gene (*FLNA*) have been found in patients suffering from non-syndromic mitral valve dysplasia (MVD). The *FLNA* protein is expressed, in particular, in endocardial endothelia during fetal valve morphogenesis and is key in cardiac development. The *FLNA*-MVD causing mutations are clustered in the N-terminal region of *FLNA*. How the mutations in *FLNA* modify its structure and function, have mostly remained elusive. In this study, using NMR spectroscopy and interaction assays, we investigated *FLNA*-MVD causing V711D and H743P mutations. Our results clearly indicated that both mutations almost completely destroy the folding of the *FLNA*5 domain, where the mutation is located, and also affect the folding of the neighboring *FLNA*4 domain. The structure of the neighboring *FLNA*6 domain was not affected by the mutations. These mutations also completely abolish *FLNA*'s interactions with protein tyrosine phosphatase (PTP) non-receptor type 12 (PTPN12), which has been suggested to contribute to the pathogenesis of *FLNA*-MVD. Taken together, our results provide an essential structural and molecular framework for understanding the molecular bases of *FLNA*-MVD, which is crucial for the development of new therapies to replace surgery.

STATEMENT OF SIGNIFICANCE

Mitral valve diseases are very common, affecting approximately 3% of the population. Currently, the only available treatment is surgery. Four different missense mutations in filamin A have been found in patients suffering from non-syndromic mitral valve dysplasia (*FLNA*-MVD). The molecular mechanism of *FLNA*-MVD has remained elusive but it is essential for development of novel drug-based therapies. In this study, we investigated two *FLNA*-MVD causing mutations in filamin. Our results clearly indicated that these mutations have critical structural effects on filamin and also affect filamin's interactions with other proteins. Taken together, our results provide an essential structural and molecular framework for understanding the molecular bases of *FLNA*-MVD, which is crucial for the development of new therapies to replace surgical options.

INTRODUCTION

Mitral valve prolapse (MVP) is a relatively common disease that affects around 3% of the world's population (1). It is also one of the most common indications for valvular surgery, and there are currently no drug-based treatments available. Nowadays, although genetic defects have definitively been associated with both syndromic and non-syndromic forms of MVP, how the mutations in the translated protein modify its structure and function has remained elusive. The filamin A gene (*FLNA*) was first associated with inherited non-syndromic mitral valve dysplasia (MVD) (*FLNA*-MVD OMIM 314400) (1, 2). Today, four missense mutations (G288R, P637Q, V711D, and H743P [**Fig. 1 A**]) have been identified in *FLNA*-MVD patients, and these mutations cause thickened myxomatous Barlow-like leaflet dystrophy (2–4). In addition to the thickening of the leaflets, a patient's mitral valve apparatus presents with specific characteristics. The chordae are shorter, and the papillary muscles are displaced close to the mitral annulus. Echocardiographic evaluation has also unveiled a unique and homogeneous phenotype. In fact, the prolapse of the leaflet in systole is unusually associated with a restrictive motion in diastole in *FLNA*-MVD patients.

Filamin A (*FLNA*) (**Fig. 1 A**) is a ubiquitously expressed cytoskeletal protein (5) that is known to be one of the key proteins in cardiac development, and it is particularly expressed in endocardial endothelia during fetal valve morphogenesis. *FLNA* knockout leads to embryonic lethality with a pleomorphic array of cardiac malformations (6–8). *FLNA* is a large cytosolic protein that provides a link between the cytoskeleton and the cell surface by interacting simultaneously with both extracellular-matrix-bound integrins and the actin cytoskeleton. These interactions make possible the central role of *FLNA* in cellular mechanotransduction (9, 10).

FLNA binds to numerous proteins, including transmembrane receptors and signaling molecules (9). Therefore, FLNA has essential scaffolding functions and integrates multiple cellular behaviors during embryonic development, cellular migration, and mechanical stress responses (9, 11, 12). Structurally, FLNA is a 280 kDa homodimeric protein consisting of N-terminal actin-binding domains followed by 24 homologous immunoglobulin (Ig)-like domains, of which domains 1–15 form rod1, and domains 16–23 form rod2. Dimerization occurs via the most C-terminal Ig-domain, FLNA24. The Ig-domains 3–5 and 16–21 form tightly arranged compact substructures in otherwise flexible Ig-domain rods (13–15). Very interestingly, *FLNA*-MVD causing mutations are all clustered at the N-terminal region of rod1 (2–4) (**Fig. 1**).

Protein tyrosine phosphatase 12 (PTPN12) has been suggested to be one of the key FLNA binding partners implicated in mitral valve diseases (16, 17). PTPN12 (PTP-PEST) is a ubiquitous cytosolic protein tyrosine phosphatase that consists of an N-terminal catalytic domain and a C-terminal non-catalytic domain (18). The proline-rich domain in the C-terminal non-catalytic domain has been shown to be a key element in interactions of FLNA and PTPN12 (17, 19). Our recent studies further revealed that the main binding site of PTPN12 on FLNA is the Ig-domain 4, but the neighboring Ig-domains 3, 5, and 6 also exhibit some binding (20). PTPN12 has been shown to be essential for cellular motility and cytoskeleton dynamics (21). PTPN12 is crucial for normal embryonic development as demonstrated by the fact that PTPN12 invalidation is embryonically lethal in mice due to important vascular defects and unsuccessful liver formation. PTPN12 is also required for integrin-mediated adhesion and migration of endothelial cells, but not for their differentiation and proliferation. PTPN12 regulates Rho GTPase (18), which binds to the most C-terminal FLNA domain 24 (22). FLNA is also involved in focal adhesion signaling pathway regulation, and it has been suggested that FLNA may act as a

scaffold for the spatial organization of Rho GTPase-mediated signaling pathways (23). Our earlier studies have, indeed, shown that *FLNA*-MVD mutations deregulate the Rho/Rac1 balance and affect cellular spreading and migration resulting from increased Rho activity (16). Accordingly, PTPN12–*FLNA* interactions might contribute to the pathogenesis of *FLNA*-MVD.

The molecular bases behind valvular diseases are, in general, poorly understood. This has restricted the development of drug-based therapies, which are currently not available. We have recently reported the structural and functional consequences of *FLNA*-MVD causing a P637Q mutation located at the middle of the compact *FLNA* rod1 fragment 3–5 (20). This mutation was observed to change *FLNA*'s force resilience and abolish its interaction with protein tyrosine phosphatase PTPN12 (20). Here, by combining Nuclear Magnetic Resonance (NMR) spectroscopy with small angle X-ray scattering (SAXS) and surface plasmon resonance (SPR), we show that the missense mutations that cause *FLNA*-MVD, which are located on *FLNA*5 (V711D and H743P), destroy the folding of Ig domains 4 and 5 and abolish the ability of PTPN12 to bind to the mutated *FLNA*.

MATERIALS AND METHODS

Recombinant proteins

FLNA domains (Swiss-Prot P21333.4, aa 574–869) were cloned into a pGTvL1-SGC vector (Structural Genomics Consortium, University of Oxford) using the ligase independent method (24) and the PTPN12 fragment (Swiss-Prot Q05209.3, aa 600–780) was cloned into a pET23b vector using the method described by Duval *et al.* (16). The mutations were introduced to the desired expression constructs using the QuikChange II site-directed mutagenesis kit (Agilent Technologies, Santa Clara, CA, USA). All the expression plasmids were verified by

sequencing. The production of glutathione S-transferase (GST) fusion proteins occurred in Terrific Broth (TB, 2.4 % w/v yeast extract, 1.2 % w/v tryptone, 0.5 % w/v glycerol, 0.017 M KH_2PO_4 , 0.072 M KH_2PO_4) by the addition of Isopropyl β -D-1-thiogalactopyranoside (IPTG) to 0.4 mM at 30°C for 4–6 h using *Escherichia coli* BL21 Gold cells. Complete lysis of the cells was achieved using the EmulsiFlex-C3 homogenizer (Avestin, Ottawa, Ontario, Canada), and lysates were cleared by centrifugation at 35,000x g for 30 min at 4°C. The GST fusion proteins were captured using Protino Glutathione Agarose 4B (Macherey-Nagel, Düren, Germany), and the GST was cleaved at 4°C for 16 h using Tobacco Etch Virus (TEV) protease (Invitrogen, Life Technologies, Carlsbad, CA, USA). The TEV cleavage extended the FLNA constructs by two additional N-terminal amino acid residues, M and S. A HiLoad 26/60 Superdex 75 column (GE Healthcare, Chicago, IL, USA) was utilized in the size exclusion chromatography of the desired fragments in 20 mM Tris pH 8.0, 100 mM NaCl, 1 mM DTT using an ÄKTA prime system (GE Healthcare, Chicago, IL, USA). Amicon Ultra centrifugal devices (Merck Millipore, Burlington, MA, USA) were used for concentrating the proteins for downstream experiments. For NMR measurements, uniform ^{15}N and ^{13}C labeling of the filamin fragments were achieved using 1 g $^{15}\text{NH}_4\text{Cl}$ and 2 g D-glucose ^{13}C (Cambridge Isotope Laboratories, Inc., Tewksbury, MA, USA) per liter in M9 media. The proteins were expressed in BL21 Gold cells for 20 h at 25°C after induction with 1 mM IPTG. The verification of homodispersity of each protein was done by analytical gel filtration (in Supporting Material, **Fig. S1**) and SDS-PAGE. 6-His tagged PTPN12 fragments were also produced in BL21 and purified on nickel beads (Macherey-Nagel, Düren, Germany) using an imidazole 250 mM elution as previously described by Duval *et al.* (16). Purified proteins were dialyzed against phosphate buffer solution (8 mM Na_2HPO_4 , 2 mM

KH₂PO₄, pH 7.8, 137 mM NaCl, 2.7 mM KCl) and quantified and analyzed by SDS-PAGE before use in SPR experiments.

FLNA6 homology model

The homology model of FLNA6 was built in two steps: (1) The sequence alignment of FLNA6 and template structure of FLNA5 (PDB ID 4M9P) (14) were constructed using the MALIGN tool in Bodil software (25) by employing a structure-based matrix (26) with a gap penalty of 40, and (2) the sequence-alignment-based model of FLNA6 was built using the nest tool in Jackal software (Honig Lab, New York, NY, USA) (27).

NMR

NMR samples were prepared in 20 mM NaH₂PO₄, 50 mM NaCl, 1 mM DTT buffer at pH 6.50, and then D₂O was added to obtain 4% solutions. Protein concentrations were 0.5–1.1 mM. All NMR spectra were collected using a Bruker Avance III HD 800MHz NMR spectrometer (Bruker, Billerica, MA, USA), equipped with a cryogenically cooled TCI ¹H, ¹³C, ¹⁵N triple resonance probehead. The data were collected at 25°C. For the assignment of backbone chemical shifts, the following experiments were conducted: ¹H, ¹⁵N HSQC (heteronuclear single quantum correlation), TROSY (Transverse Relaxation Optimized Spectroscopy) -HNCA, TROSY-HN(CO)CA, TROSY-HNCACB, and TROSY-HN(CO)CACB (for review, see (28)). All spectra were processed with TopSpin 3.5 and analyzed with NMRFAM-Sparky 1.4 (29). Time delays for ¹⁵N T₁ relaxation data were 20, 100, 200, 400, 800, 1100, and 1400 ms. An exponentially decaying curve was fitted to the peak intensities, as implemented in Dynamic Center software (Bruker, Billerica, MA, USA). Chemical shift assignments of FLNA4–6 have

been submitted to the Biological Magnetic Resonance Data Bank (BMRB) with accession code 27795.

HYDRONMR (30) was used to calculate the theoretical ^{15}N T_1 relaxation times at 303.13 K, using 0.008 poises for the solvent viscosity at 18.10 Tesla magnetic field. The relaxation data were calculated separately for the FLNA4–5 structure taken from the FLNA3–5 crystal structure (PDB ID 4M9P) (14) and the FLNA6 homology model.

Limited proteolysis

Samples prepared in 20 mM Tris, pH 8.0, 100 mM NaCl, 1 mM DTT were exposed to proteolytic digestion at 20°C by α -chymotrypsin (Sigma-Aldrich, St. Louis, MO, USA) using a mass ratio of 1:1000. Protein fragments obtained from various incubation intervals were separated on 12% gels using SDS-PAGE. The entire experiment was conducted in triplicate, resulting in reproducible degradation patterns.

SAXS

A BM29 beamline (ESRF, Grenoble, France) was used to collect the SAXS data on a PILATUS 1M image plate using a sample to detector distance of 2.9 m and a wavelength of 1.0 Å (momentum transfer range $0.01 < q < 5 \text{ nm}^{-1}$). Three different protein concentrations (1.0, 2.0, and 4.0 mg/ml) were used in the data acquisition. Prior to measurements, fresh DTT was added to 10 mM in the gel filtration buffer. The ATSAS software package (EMBL, Hamburg, Germany) was utilized in the data processing (31). Guinier analysis performed using PRIMUS (32) and distance distribution functions calculated using DATGNOM (33) provided the estimates for the radius of gyration (R_g) and maximum dimensions (D_{max}) of the particles. Apparent

particle aggregation or repulsion was excluded in the Guinier analysis. The Porod volumes were estimated using the DATPOROD program in ATSAS (31). DAMMIF (34) on ATSAS online (<https://www.embl-hamburg.de/biosaxs/atsas-online>) was used for generating a total of 20 *ab initio* shape envelopes that were subsequently aligned against the most probable model, then averaged, and ultimately filtered in DAMAVER (35). The resolution of the *ab initio* models were ultimately estimated using SASRES (36). The FLNA4–6 rigid body model was obtained using SASREF (37), and the final overlaying of the crystal structures and the *ab initio* models was achieved using SUPCOMB (38). The flexibility of the selected FLNA fragments was examined using the ensemble optimization method (EOM) (39, 40) on ATSAS online. In the WT EOM calculations, the FLNA4 and FLNA5 crystal structures and the FLNA6 model were used as rigid bodies. In the mutant protein EOM calculations, the FLNA4–5 domain pair was set as a random coil, while the FLNA6 model was provided as a structured domain. The WT fragments were analyzed using merged scattering data, whereas the mutated FLNA4–6 fragments data from a single protein concentration (4 mg/ml) was used. In addition, a control run for the FLNA4–6 WT fragment utilizing the mutant EOM parameters and WT SAXS data was performed. CORAL (41) was utilized to study the domain movements and the flexibility of the linker between the FLNA4–5 domain pair and the FLNA6 domain. In CORAL calculations, FLNA4–5 was kept in the fixed orientation, whereas the linker region and FLNA6 (aa 767–869) moved freely. The solution scattering of the selected atomic models obtained from CORAL and SASREF was evaluated using CRY SOL (42). The statistics from all of the SAXS analyses are shown in **Tables S1 through S3** in the Supporting Material. The SAXS images were prepared using the PyMOL Molecular Graphics System, version 0.99 (Schrödinger, LCC, New York, NY, USA) and GraphPad Prism 8 (GraphPad Software, San Diego, CA, USA). The SAXS data have been

submitted to SASBDB with the accession codes SASDFD3 (FLNA4–6 WT), SASDFE3 (FLNA4–6 V711D, 4 mg/ml), SASDFF3 (FLNA4–6 V711D, 2 mg/ml), SASDFG3 (FLNA4–6 H743P, 4 mg/ml), and SASDFH3 (FLNA4–6 WT H743P, 2 mg/ml).

Surface plasmon resonance experiments

The SPR experiments were conducted on the BIAcore 3000 system (GE Healthcare, Chicago, IL, USA). The experiments were carried out at 25°C using HBS-EP (0.01 M HEPES; pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% v/v P20) as the running buffer. Purified PTPN12 fragments were immobilized on CM5 sensor chips (GE Healthcare, Chicago, IL, USA) by amine coupling, as recommended by the manufacturer for about 200–300 resonance units (RU). Samples of purified FLNA4–6 and the corresponding mutated fragments, V711D and H743P, were diluted in the running buffer and injected in single-cycle kinetics (SCK) mode at five different concentrations (0.31, 0.62, 1.25, 2.50, and 5.00 μ M) using a flow rate of 30 μ l/min over the chip surface. Binding surfaces were regenerated to remove bound analyte by injecting 50 mM NaOH for 30 s. This regeneration condition removed analyte completely but retained the surface binding capacity of the PTPN12 functionalized chip. Kinetic constants were calculated by global fitting of the data to a 1:1 Langmuir binding model (SCK) after subtracting the control surface, using the BIAevaluation software, version 4.0.1 (GE Healthcare, Chicago, IL, USA).

RESULTS

Mutations at FLNA5 destroy the compact FLNA rod1 structure

In order to get information about how the MVP-causing mutations V711D and H743P located at FLNA5 effect FLNA structure, the mutations were inserted in the three-domain fragment consisting of domains from 4 to 6. This construct was used because it has flanking

FLNA domains on both sides of the mutated FLNA5 domain providing a reliable model of the full length FLNA for *in vitro* structural studies. First, the analytical size exclusion analyses of WT and mutated FLNA4–6 fragments showed that the retention volumes of mutants are smaller than that of the WT fragment, indicating that mutations affect the shapes of FLNA4–6 (**Fig. S1**). SAXS was then employed to more closely study the effects of V711D and H743P mutations on FLNA4–6 structure (**Table S1**). The direct comparison of the forward scattering curves (**Fig. 2 A and S2**) and the corresponding Kratky, Porod, and distance distribution $P(r)$ plots (43) (**Fig. 2 B, C, and D**) of the WT and mutant proteins suggest structural unfolding of the V711D and H743P fragments. The EOM analyses of FLNA4–6 WT and mutant SAXS data provide further support for the structural misfolding of FLNA4–6 V711D and H743P fragments, as both the R_g and D_{max} distributions are much wider than those of the WT fragment (**Fig. S3, Table S3**). Also, for mutants, more structures, 14 (V711D) and 17 (H743P) are needed to fit the experimental data than for WT FLNA4-6 (four structures, **Table S3**).

It should, however, be kept in mind that SAXS only gives the average data of the entire FLNA4–6 fragment. Therefore, NMR spectroscopy was then employed to collect domain-level information about the effects of the V711D and H743P mutations on the structure of the FLNA4–6 fragment. First, the ^{15}N -HSQC spectra for FLNA4–6 WT, V711D and H743P, were measured. The HSQC spectrum of the WT fragment (**Fig. 2 E**) was drastically different than those of the mutants, which were similar to each other (**Fig. 2 F and G**). The ^{15}N -HSQC spectrum of FLNA4–6 WT (**Fig. 2 E**) showed good dispersion of the cross peaks, with rather similar intensities, as can be expected for a modular protein having three homologous, well-structured, domains. In contrast, the ^{15}N - ^1H correlation spectra of both mutants lack the vast majority of the NH cross peaks in the structural fingerprint region (> 8.5 ppm). Moreover, the

high intensity NH cross peaks cluster in the middle of the $^1\text{H}^{\text{N}}$ chemical shift range (7.7–8.5 ppm ^1H), indicating an improperly folded domain and the prevalence of structural disorder (**Fig. 2 F and G**).

In order to be able to analyze and compare all three spectra in more detail, the backbone assignment of FLNA4–6 WT was carried out using the triple-resonance HNCA, HN(CO)CA, HNCACB, and HN(CO)CACB experiments with implementation of the transverse relaxation optimized spectroscopy (TROSY) (28). The close comparison of the ^{15}N -HSQC spectra of FLNA4–6 WT and FLNA4–6 V711D and H743P mutants indicated that most of the cross peaks corresponding to domain 5 and, interestingly, also to domain 4 were missing from the V711D and H743P ^{15}N -HSQC spectra, whereas the cross peaks corresponding to domain 6 could still be found in the mutant spectra (**Fig. 2 E and G**). In addition to the high-intensity cross peaks, the ^{15}N -HSQC spectra of the mutants also exhibit several broadened NH resonances, likely originating in domains 4 and 5. This suggests the presence of μ -ms timescale motions within FLNA4–5.

The almost complete unfolding of FLNA4–5 increased its susceptibility to proteolytic cleavage, as seen in **Fig. 3 B**. Controlled protease digestion assays showed that FLNA4–6 V711D and H743P were significantly more readily digested by chymotrypsin than FLNA4–6 WT. At the 60 min time point, the FLNA4–6 WT was largely intact, whereas practically no full-length species were left for mutant proteins. Simultaneously, as the full-length FLNA4–6 mutant fragments were digested by chymotrypsin, a new band corresponding to approximately a 10 kDa protein fragment formed. This could be the FLNA6 domain that, as a folded domain, is not prone to proteolysis, but we have no proof for that.

Taken together, the data obtained from SAXS and NMR spectroscopy as well as from limited proteolysis indisputably showed that the *FLNA*-MVD causing V711D and H743P mutations almost completely destroyed the folding of the mutated FLNA5 as well as, interestingly, FLNA4.

FLNA6 is not part of the compact rod1 fragment and not affected by FLNA-MVD mutations

To date, the detailed atomic structure of FLNA4–6 remains undetermined. Domains 4 and 5 are known to form a compact structure, both in the crystal structure (**Fig. 1 B**) and in solution (14) but the orientation of FLNA6 with respect to FLNA5 has remained enigmatic. Both SAXS and NMR spectroscopy were employed to solve the overall structure of FLNA4–6 to get information about how FLNA5 mutation affects the overall rod1 structure. The comparison of FLNA3–5 and FLNA4–6 scattering curves shown in **Fig. 3 C** reveals that the effect of the domain 6 to FLNA4–5 structure is different than that of domain 3. The *ab initio* model calculated from SAXS data shows that the shape of FLNA4–6 (**Fig. 3 D** and **Table S2**) is elongated, whereas FLNA3–5 is more rounded (**Fig. 3 E**). The calculated SAXS-based rigid body model of the FLNA4–6 fragment reveals that domain 6 did not interact with FLNA4–5 (**Fig. 3 D**). The rigid body model of FLNA4–6 nicely fits with the *ab initio* envelope (**Fig. 3 D**), similar to the FLNA3–5 crystal structure (**Fig. 3 E** (14)). Also, the molecular dimensions obtained from SAXS measurements revealed that FLNA4–6 is 2.4 nm longer than the compact FLNA3–5 fragment (14, 20) (**Fig. 3 D, Fig. 3 E, and Table S1**), indicating that FLNA6 is not as tightly packed as FLNA5.

To further investigate FLNA6 motion restrictions with respect to FLNA5, the ^{15}N T_1 relaxation times were measured using NMR spectroscopy. A plot of ^{15}N T_1 values versus amino

acid sequence is shown in **Fig. 3 A**. The average T_1 values are clearly higher for FLNA4 and FLNA5 in comparison to FLNA6. This indicates that rather than being ‘pearls on a string,’ FLNA4 and 5 are tumbling as a larger structural unit with respect to FLNA6, and that tumbling of FLNA6 is minimally restricted with respect to FLNA4–5. In order to compare estimated ^{15}N spin relaxation times for the separate FLNA4–5 and FLNA6 constructs, we simulated relaxation times for the FLNA4–5 crystal structure (PDB ID 4M9P) (14) and homology model of FLNA6 using HYDRONMR software (30) (**Fig. S4**). It is evident that while expected ^{15}N T_1 values showed similar trends between the simulated and experimental values, meaning that elevated ^{15}N T_1 times were observed for the FLNA4 and 5 domains, the absolute ^{15}N T_1 values for the separate FLNA4–5 and FLNA6 domains were generally lower in simulated data. This indicates that molecular tumbling of FLNA6 is hindered by FLNA4–5, and vice versa, in the FLNA4–6 construct, resulting in slower overall tumbling. The CORAL based modeling of the SAXS data was then used to further investigate the motions of FLNA6 in respect to the FLNA4–5 domain pair. The results presented in **Fig. 3 F** show that FLNA6, connected by a short flexible linker to FLNA5, can adopt various orientations with respect to FLNA4–5. All these different orientations fit well to the experimental scattering data of FLNA4–6 (χ^2 -values 0.92-1.09, Table S2). The results from CORAL based modelling of the SAXS data are in accordance with the results from EOM calculations, where four structures were needed to fit the experimental data (**Table S3**), instead of one structure which would have represented the rigid structure.

Combining the results obtained from both SAXS and NMR studies suggested that FLNA6 does not interact with FLNA5, and its motion is only partially restricted by FLNA4–5 (**Fig. 3 A, D, F, and S4**). Accordingly, FLNA5 mutations only destroy the compact structure of FLNA4–5, whereas FLNA5–6 is not affected by FLNA5 mutations.

The effects of FLNA-MVD mutation on FLNA's interactions

FLNA executes many of its functions via interactions with other proteins (9, 44, 45). Accordingly, the obvious mechanism for *FLNA*-MVD caused by the mutations would be the altered interactions with other proteins, followed by effects on downstream signaling. Most FLNA binding partners have been mapped to rod2 domains, whereas only a few proteins have been shown to interact with rod1 domains. One of the rod1 interacting proteins is PTPN12. Recently, we have shown that the proline-rich domain (Pro4) of the C-terminal domain of PTPN12 binds FLNA domains 4–6, of which FLNA4 is the main binding site (20). Using SPR, we tested whether V711D and H743P mutations affect FLNA–PTPN12 interactions. Although an affinity constant of K_d 3.3×10^{-7} M was determined for the FLNA4–6 WT–PTPN12 interaction from the sensorgrams obtained using FLNA4–6 as an analyte on immobilized PTPN12 C-terminal fragment (aa 600–780) (20), the K_d was barely measurable for mutant recombinant FLNA-V711D and H743P (**Fig. 4**).

DISCUSSION

To date, the molecular bases of valvular diseases have been poorly understood, and this has restricted the development of new therapies to replace surgical treatment. In this study, we sought and found a molecular-level explanation of why the FLNA mutations V711D and H743P cause *FLNA*-MVD.

Our results clearly reveal that the FLNA mutations V711D and H743P both have structural consequences. Integrative approach utilizing NMR spectroscopy and SAXS measurements unambiguously indicated that the missense mutations destroyed the folding of the

particular domain where the mutation was located. This is not surprising, as the hydrophobic valine residue, which points toward the hydrophobic interior of the Ig domain of FLNa5 (**Fig. 1 B**), is mutated to a negatively charged and slightly larger aspartic acid residue, causing both electrostatic and steric conflicts that destroy domain folding. H743, in turn, is located in the middle of the β -strand (**Fig. 1 B**). Accordingly, the mutation to proline residue destroys the β -strand and consequently affects the stability of the neighboring β -strands and the entire Ig-domain. Importantly, the FLNA5 mutations V711D and H743P were also shown to affect the stability of the neighboring N-terminal domain FLNA4, but not the neighboring C-terminal domain FLNA6. It was not surprising that the loss of the compact folding of FLNA5 affected the stability of FLNA4 as well because domain 4 had earlier been reported to be unstable when it is isolated but is stabilized by the neighboring domain 5 (14). Our results from both NMR ^{15}N spin relaxation data and SAXS measurements, in turn, demonstrated that FLNA6 is not part of the compact rod1 substructure composed from domains 3–5. Accordingly, the destabilization of the adjacent FLNA5 domain does not influence the stability of FLNA6.

In cardiac valves, FLNA is submitted to intense hemodynamic stresses. Our recent study revealed that the P637Q mutation affects FLNA's force resilience (20). With P637Q mutated FLNA, significantly lower forces were needed to detach FLNA4 and FLNA5 domains from each other than with WT FLNA. It can be speculated that V711D and H743P mutations also change FLNA's ability to respond to forces because they destroy the compact and force-regulated rod1 substructure, making it inherently flexible and devoid of any force resilience ability. Several other disease-causing mutations have also been identified from FLNA. Interestingly, although disease-causing mutations are spread through FLNA, many are clustered in the compact FLNA regions of FLNA3–5 and FLNA16–17 (46–50). A skeletal dysplasia-causing mutation at

FLNA16 has also been reported to change FLNA's ability to respond to force (51). Accordingly, it seems that defects in FLNA's force resilience might be involved in the pathogenesis of various FLNA-linked diseases. This could be expected because FLNA is known to be crucial for cellular force transmission (10). The connection of FLNA and mechanosensing is especially strong in the development and progression of cardiac diseases due to defects in mechanosensing known to cause various cardiac diseases (52–54). Moreover, FLNA is strongly expressed in endocardial cells during cardiac morphogenesis (12).

The almost complete unfolding of two FLNA domains, 4 and 5, also increased proteolytic digestion of FLNA. This might, of course, be one possible mechanism behind *FLNA*-MVD, although no *in vivo* data of the degradation of FLNA in *FLNA*-MVD has been reported. Similar FLNA domain unfolding due to disease-causing mutations have been reported, with FLNb17 mutations causing skeletal dysplasia called Larsen syndrome (51).

Our results also revealed that FLNA5 mutations abolished FLNA's interactions with PTPN12. The main binding site of PTPN12 has been mapped to domain 4 (20). The P637Q mutation that is located at FLNA4 has recently been reported to prevent the PTPN12 interaction. FLNA5–PTPN12 interaction is, however, very weak (20). As the FLNA5 mutations V711D and H743P not only destroy the folding of domain 5 but also FLNA4, it is not surprising that these mutations also abolish PTPN12 binding to FLNA. Other proteins, such as protein kinase Syk (55) and DPP9 (56), have also been mapped to bind FLNA5. The loss of FLNA5 folding due to *FLNA*-MVD mutations obviously abolished their binding to FLNA as well. Whether Syk or DPP9 have roles in *FLNA*-MVD pathogenesis is not known.

Taken together, the underlying mechanism behind *FLNA*-MVD seems to be linked to the unfolding of FLNA4 and FLNA5, which might cause the proteolytic digestion of cells, abolish

PTPN12 interaction, and potentially also affect FLNA's force resilience. Which one of these is the most essential molecular mechanism is not known. The importance of FLNA misfolding in the *FLNA*-MVD pathogenesis provides a tempting idea to use molecular chaperones (57) as therapeutic treatment of *FLNA*-MVD.

CONCLUSIONS

Cardiac valve diseases are common, affecting 3% of the population. Currently, no treatments other than cardiac surgery are available, but surgery is expensive and has high levels of risk. However, the lack of structural level information of the proteins involved has restricted the development of new therapies. The results presented here with regard to structural and functional consequences of *FLNA*5 mutations, together with recently reported *FLNA*4 mutations, suggest that both *FLNA* force resilience and interaction with PTPN12 are important for *FLNA*-MVD pathogenesis. Although our results do not provide a complete molecular-level explanation for *FLNA*-MVD, they provide a crucial step toward understanding the underlying molecular mechanism behind valvular dystrophy and a possible objective for the development of drug-based therapeutics.

Author contributions

TH: Validation, Formal analysis, Investigation, Writing – original draft, Writing – Review & Editing, Visualization. RC: Formal analysis, Investigation. SL: Formal analysis, Investigation. MH: Supervision. JM: Writing – original draft, Writing – Review & Editing, Supervision, Funding Acquisition. PP: Validation, Formal analysis, Investigation, Writing – original draft, Writing – Review & Editing, Supervision, Funding Acquisition. UP: Validation,

Formal analysis, Investigation, Writing – original draft, Writing – Review & Editing, Supervision, Project Administration, Funding Acquisition.

Acknowledgements

ESRF is thanked for providing the beamline BM29 access. We thank Mike Maillason 1-Plateforme IMPACT Biogenouest - SFR François Bonamy - Université de Nantes for his technical expertise in SPR experiments. This work was supported by Academy of Finland [283481 to U.P, and 288235 to P.P] and the Fédération Française de Cardiologie (2011, Paris, France to J.M) and Inserm Translational Research Grant (2012-2016, Paris, France). Dr. R Capoulade is supported by a grant from Institut de France - Fondation Lefoulon-Delalande (Paris, France) and a “Connect Talent” research chair from Region Pays de la Loire and Nantes Metropole (France).

Declaration of Interests

The authors declare no competing financial interests.

Supporting Citations

References 20, 30-34, 36, 37 and 39-43 appear in the supporting material.

References

1. Levine, R.A., A.A. Hagège, D.P. Judge, M. Padala, J.P. Dal-Bianco, E. Aikawa, J. Beaudoin, J. Bischoff, N. Bouatia-Naji, P. Bruneval, J.T. Butcher, A. Carpentier, M. Chaput, A.H. Chester, C. Clusel, F.N. Delling, H.C. Dietz, C. Dina, R. Durst, L. Fernandez-Friera, M.D. Handschumacher, M.O. Jensen, X.P. Jeunemaitre, H. Le Marec, T. Le Tourneau, R.R. Markwald, J. Mérot, E. Messas, D.P. Milan, T. Neri, R.A. Norris, D. Peal, M. Perrocheau, V. Probst, M. Pucéat, N. Rosenthal, J. Solis, J.-J. Schott, E. Schwammenthal, S.A. Slaugenhaupt, J.-K. Song, and M.H. Yacoub. 2015. Mitral valve disease—morphology and mechanisms. *Nat. Rev. Cardiol.* 12: 689–710.
2. Kyndt, F., J.P. Gueffet, V. Probst, P. Jaafar, A. Legendre, F. Le Bouffant, C. Toquet, E. Roy, L. McGregor, S.A. Lynch, R. Newbury-Ecob, V. Tran, I. Young, J.N. Trochu, H. Le Marec, and J.J. Schott. 2007. Mutations in the gene encoding filamin A as a cause for familial cardiac valvular dystrophy. *Circulation.* 115: 40–49.
3. Bernstein, J.A., D. Bernstein, U. Hehr, and L. Hudgins. 2011. Familial cardiac valvulopathy due to filamin A mutation. *Am. J. Med. Genet. Part A.* 155: 2236–2241.
4. Le Tourneau, T., S. Le Scouarnec, C. Cueff, D. Bernstein, J.J.J. Aalberts, S. Lecointe, J. Mérot, J.A. Bernstein, T. Oomen, C. Dina, M. Karakachoff, H. Desal, O. Al Habash, F.N. Delling, R. Capoulade, A.J.H. Suurmeijer, D. Milan, R.A. Norris, R. Markwald, E. Aikawa, S.A. Slaugenhaupt, X. Jeunemaitre, A. Hagège, J.-C. Roussel, J.-N. Trochu, R.A. Levine, F. Kyndt, V. Probst, H. Le Marec, and J.-J. Schott. 2017. New insights into mitral valve dystrophy: a Filamin-A genotype–phenotype and outcome study. *Eur. Heart J.* : 1–9.
5. Flier, A. Van Der, and A. Sonnenberg. 2001. Structural and functional aspects of filamins. *BBA.* 1538: 99–117.

6. Feng, Y., M.H. Chen, I.P. Moskowitz, A.M. Mendonza, L. Vidali, F. Nakamura, D.J. Kwiatkowski, and C.A. Walsh. 2006. Filamin A (FLNA) is required for cell-cell contact in vascular development and cardiac morphogenesis. *Proc. Natl. Acad. Sci. U. S. A.* 103: 19836–19841.
7. Stossel, T.P., J. Condeelis, L. Cooley, J.H. Hartwig, a Noegel, M. Schleicher, and S.S. Shapiro. 2001. Filamins as integrators of cell mechanics and signalling. *Nat. Rev. Mol. Cell Biol.* 2: 138–145.
8. Sauls, K., A. De Vlaming, B.S. Harris, K. Williams, A. Wessels, R.A. Levine, S.A. Slaughaupt, R.L. Goodwin, L.M. Pavone, J. Merot, J.J. Schott, T. Le Tourneau, T. Dix, S. Jesinkey, Y. Feng, C. Walsh, B. Zhou, S. Baldwin, R.R. Markwald, and R.A. Norris. 2012. Developmental basis for filamin-A-associated myxomatous mitral valve disease. *Cardiovasc. Res.* 96: 109–119.
9. Zhou, A.-X., J.H. Hartwig, and L.M. Akyürek. 2010. Filamins in cell signaling, transcription and organ development. *Trends Cell Biol.* 20: 113–123.
10. Ehrlicher, A.J., F. Nakamura, J.H. Hartwig, D. Weitz, and T.P. Stossel. 2011. Mechanical strain in actin networks regulates FilGAP and integrin binding to filamin A. *Nature.* 478: 260–263.
11. Baldassarre, M., Z. Razinia, C.F. Burande, I. Lamsoul, P.G. Lutz, and D. Calderwood. 2009. Filamins regulate cell spreading and initiation of cell migration. *PLoS One.* 4: e7830.
12. Norris, R.A., R. Moreno-Rodriguez, A. Wessels, J. Merot, P. Bruneval, A.H. Chester, M.H. Yacoub, A. Hagège, S.A. Slaughaupt, E. Aikawa, J.J. Schott, A. Lardeux, B.S. Harris, L.K. Williams, A. Richards, R.A. Levine, and R.R. Markwald. 2010. Expression

- of the familial cardiac valvular dystrophy gene, filamin-A, during heart morphogenesis. *Dev. Dyn.* 239: 2118–2127.
13. Ruskamo, S., R. Gilbert, G. Hofmann, P. Jiang, I.D. Campbell, J. Yläne, and U. Pentikäinen. 2012. The C-terminal rod 2 fragment of filamin A forms a compact structure that can be extended. *Biochem. J.* 446: 261–269.
 14. Sethi, R., J. Seppälä, H. Tossavainen, M. Ylilauri, S. Ruskamo, O.T. Pentikäinen, U. Pentikäinen, P. Permi, and J. Yläne. 2014. A novel structural unit in the N-terminal region of filamins. *J. Biol. Chem.* 289: 8588–8598.
 15. Sethi, R., and J. Yläne. 2014. Small-Angle X-Ray Scattering Reveals Compact Domain-Domain Interactions in the N-Terminal Region of Filamin C. *PLoS One.* 9: e107457.
 16. Duval, D., A. Lardeux, T. Le Tourneau, R.A. Norris, R.R. Markwald, V. Sauzeau, V. Probst, H. Le Marec, R. Levine, J.J. Schott, and J. Merot. 2014. Valvular dystrophy associated filamin A mutations reveal a new role of its first repeats in small-GTPase regulation. *Biochim. Biophys. Acta - Mol. Cell Res.* 1843: 324–334.
 17. Duval, D., P. Labbé, L. Bureau, T. Le Tourneau, R.A. Norris, R.R. Markwald, R. Levine, J.-J. Schott, and J. Mérot. 2015. MVP-Associated Filamin A Mutations Affect FlnA-PTPN12 (PTP- PEST) Interactions. *J. Cardiovasc. Dis.* 2: 233–247.
 18. Zhen, Y., and L. Zhimin. 2013. Regulation of tumor cell migration by protein tyrosine phosphatase (PTP)-proline-, glutamate-, serine-, and threonine-rich sequences. *Chinese J. Cancer.* 32: 75–83.
 19. Playford, M.P., P.D. Lyons, S.K. Sastry, and M.D. Schaller. 2006. Identification of a filamin docking site on PTP-PEST. *J. Biol. Chem.* 281: 34104–34112.
 20. Haataja, T.J.K., R.C. Bernardi, S. Lecointe, R. Capoulade, J. Merot, and U. Pentikäinen.

2019. Non-syndromic Mitral Valve Dysplasia Mutation Changes the Force Resilience and Interaction of Human Filamin A. *Structure*. 27: 1–11.
21. Östman, A., C. Hellberg, and F.D. Böhmer. 2006. Protein-tyrosine phosphatases and cancer. *Nat. Rev. Cancer*. 6: 307–320.
22. Nakamura, F., T.P. Stossel, and J.H. Hartwig. 2011. The filamins: organizers of cell structure and function. *Cell Adh Migr*. 5: 160–169.
23. Bellanger, J.M., C. Astier, C. Sardet, Y. Ohta, T.P. Stossel, and A. Debant. 2000. The Rac1- and RhoG-specific GEF domain of trio targets filamin to remodel cytoskeletal actin. *Nat. Cell Biol*. 2: 888–892.
24. Gileadi, O., N.A. Burgess-Brown, S.M. Colebrook, G. Berridge, P. Savitsky, C.E.A. Smee, P. Loppnau, C. Johansson, E. Salah, and N.H. Pantic. 2008. High Throughput Production of Recombinant Human Proteins for Crystallography. 426: 221–246.
25. Lehtonen, J. V, D.J. Still, V. V Rantanen, J. Ekholm, D. Björklund, Z. Iftikhar, M. Huhtala, S. Repo, A. Jussila, J. Jaakkola, O. Pentikäinen, T. Nyrönen, T. Salminen, M. Gyllenberg, and M.S. Johnson. 2004. BODIL: a molecular modeling environment for structure-function analysis and drug design. *J. Comput. Mol. Des. J. Comput. Mol. Des.* 18: 401–419.
26. Johnson, M.S., and J.P. Overington. 1993. A structural basis for sequence comparisons. An evaluation of scoring methodologies. *J. Mol. Biol*. 233: 716–783.
27. Petrey, D., Z. Xiang, C.L. Tang, L. Xie, M. Gimpelev, T. Mitros, C.S. Soto, S. Goldsmith-fischman, A. Kernytsky, A. Schlessinger, I.Y.Y. Koh, E. Alexov, and B. Honig. 2003. Using Multiple Structure Alignments , Fast Model Building , and Energetic Analysis in Fold Recognition and Homology Modeling. *PROTEINS Struct. Funct. Genet*. 53: 430–

- 435.
28. Permi, P., and A. Annala. 2004. Coherence transfer in proteins. *Prog. Nucl. Magn. Reson. Spectrosc.* 44: 97–137.
 29. Lee, W., M. Tonelli, and J.L. Markley. 2014. NMRFAM-SPARKY: enhanced software for biomolecular NMR spectroscopy. *Bioinformatics.* 31: 1325–1327.
 30. Schuler, B. 2018. Perspective: Chain dynamics of unfolded and intrinsically disordered proteins from nanosecond fluorescence correlation spectroscopy combined with single-molecule FRET. *J. Chem. Phys.* 149: 1–10.
 31. Franke, D., M. V. Petoukhov, P. V. Konarev, A. Panjkovich, A. Tuukkanen, H.D.T. Mertens, A.G. Kikhney, N.R. Hajizadeh, J.M. Franklin, C.M. Jeffries, and D.I. Svergun. 2017. ATSAS 2.8: A comprehensive data analysis suite for small-angle scattering from macromolecular solutions. *J. Appl. Crystallogr.* 50: 1212–1225.
 32. Konarev, P. V, V. V Volkov, A. V Sokolova, M.H.J. Koch, and D.I. Svergun. 2003. PRIMUS : a Windows PC-based system for small-angle scattering data analysis. *J. Appl. Crystallogr.* 36: 1277–1282.
 33. Petoukhov, M. V, P. V Konarev, A.G. Kikhney, and D.I. Svergun. 2007. ATSAS 2.1 - Towards automated and web-supported small-angle scattering data analysis. *J. Appl. Crystallogr.* 40: 223–228.
 34. Franke, D., and D.I. Svergun. 2009. *DAMMIF* , a program for rapid *ab-initio* shape determination in small-angle scattering. *J. Appl. Crystallogr.* 42: 342–346.
 35. Volkov, V. V., and D.I. Svergun. 2003. Uniqueness of *ab initio* shape determination in small-angle scattering. *J. Appl. Crystallogr.* 36: 860–864.
 36. Tuukkanen, A.T., G.J. Kleywegt, and D.I. Svergun. 2016. Resolution of *ab initio* shapes

- determined from small-angle scattering. *Int. Union Crystallogr.* 3: 440–447.
37. Petoukhov, M. V., and D.I. Svergun. 2005. Global rigid body modeling of macromolecular complexes against small-angle scattering data. *Biophys. J.* 89: 1237–1250.
 38. Kozin, M.B., and D.I. Svergun. 2001. Automated matching of high- and low-resolution structural models research papers Automated matching of high- and low-resolution structural models. *J. Appl. Crystallogr.* 34: 33–41.
 39. Tria, G., H.D.T. Mertens, M. Kachala, and D.I. Svergun. 2015. Advanced ensemble modelling of flexible macromolecules using X-ray solution scattering. *IUCrJ.* 2: 207–217.
 40. Bernadó, P., E. Mylonas, M. V Petoukhov, M. Blackledge, and D.I. Svergun. 2007. Structural characterization of flexible proteins using small-angle X-ray scattering. *J. Am. Chem. Soc.* 129: 5656–64.
 41. Petoukhov, M. V., D. Franke, A. V. Shkumatov, G. Tria, A.G. Kikhney, M. Gajda, C. Gorba, H.D.T. Mertens, P. V. Konarev, and D.I. Svergun. 2012. New developments in the ATSAS program package for small-angle scattering data analysis. *J. Appl. Crystallogr.* 45: 342–350.
 42. Svergun, D., C. Barberato, and M.H. Koch. 1995. CRY SOL - A program to evaluate X-ray solution scattering of biological macromolecules from atomic coordinates. *J. Appl. Crystallogr.* 28: 768–773.
 43. Rambo, R.P., and J.A. Tainer. 2012. Characterizing Flexible and Intrinsically Unstructured Biological Macromolecules by SAS using the Porod-Debye Law. *Biopolymers.* 95: 559–571.
 44. Nakamura, F., T.M. Osborn, C. a Hartemink, J.H. Hartwig, and T.P. Stossel. 2007.

- Structural basis of filamin A functions. *J. Cell Biol.* 179: 1011–1025.
45. Razinia, Z., T. Mäkelä, J. Ylännä, and D. Calderwood. 2012. Filamins in mechanosensing and signaling. *Annu. Rev. Biophys.* 41: 227–246.
 46. Robertson, S.P., Z. a Jenkins, T. Morgan, L. Adès, S. Aftimos, O. Boute, T. Fiskerstrand, S. Garcia-Miñaur, A. Grix, A. Green, V. Der Kaloustian, R. Lewkonja, B. McInnes, M.M. Van Haelst, G. Mancini, T. Illés, G. Mortier, R. Newbury-Ecob, L. Nicholson, C.I. Scott, K. Ochman, I. Brozek, D.J. Shears, A. Superti-Furga, M. Suri, M. Whiteford, A.O.M. Wilkie, and D. Krakow. 2006. Frontometaphyseal dysplasia: mutations in FLNA and phenotypic diversity. *Am. J. Med. Genet. Part A.* 140: 1726–1736.
 47. Robertson, S.P., S.R.F. Twigg, A.J. Sutherland-Smith, V. Biancalana, R.J. Gorlin, D. Horn, S.J. Kenwrick, C. a Kim, E. Morava, R. Newbury-Ecob, K.H. Orstavik, O.W.J. Quarrell, C.E. Schwartz, D.J. Shears, M. Suri, J. Kendrick-Jones, and A.O.M. Wilkie. 2003. Localized mutations in the gene encoding the cytoskeletal protein filamin A cause diverse malformations in humans. *Nat. Genet.* 33: 487–491.
 48. Robertson, S.P. 2007. Otopalatodigital syndrome spectrum disorders: otopalatodigital syndrome types 1 and 2, frontometaphyseal dysplasia and Melnick-Needles syndrome. *Eur. J. Hum. Genet.* 15: 3–9.
 49. Daniel, P.B., T. Morgan, Y. Alanay, E. Bijlsma, T.-J. Cho, T. Cole, F. Collins, A. David, K. Devriendt, L. Faivre, S. Ikegawa, S. Jacquemont, M. Jesic, D. Krakow, D. Liebrecht, S. Maitz, S. Marlin, G. Morin, T. Nishikubo, G. Nishimura, T. Prescott, G. Scarano, Y. Shafeghati, F. Skovby, S. Tsutsumi, M. Whiteford, M. Zenker, and S.P. Robertson. 2012. Disease-associated mutations in the actin-binding domain of filamin B cause cytoplasmic focal accumulations correlating with disease severity. *Hum. Mutat.* 33: 665–673.

50. Bicknell, L.S., C. Farrington-Rock, Y. Shafeghati, P. Rump, Y. Alanay, Y. Alembik, N. Al-Madani, H. Firth, M.H. Karimi-Nejad, C.A. Kim, K. Leask, M. Maisenbacher, E. Moran, J.G. Pappas, P. Prontera, T. de Ravel, J.-P. Fryns, E. Sweeney, A. Fryer, S. Unger, L.C. Wilson, R.S. Lachman, D.L. Rimoin, D.H. Cohn, D. Krakow, and S.P. Robertson. 2007. A molecular and clinical study of Larsen syndrome caused by mutations in FLNB. *J. Med. Genet.* 44: 89–98.
51. Seppälä, J., R.C. Bernardi, T.J.K. Haataja, M. Hellman, O.T. Pentikäinen, K. Schulten, P. Permi, J. Yläne, and U. Pentikäinen. 2017. Skeletal Dysplasia Mutations Effect on Human Filamins ' Structure and Mechanosensing. *Sci. Rep.* 7: 4218.
52. Krüger, M., and W.A. Linke. 2009. Titin-based mechanical signalling in normal and failing myocardium. *J. Mol. Cell. Cardiol.* 46: 490–498.
53. Herum, K., I. Lunde, A. McCulloch, and G. Christensen. 2017. The Soft- and Hard-Heartedness of Cardiac Fibroblasts: Mechanotransduction Signaling Pathways in Fibrosis of the Heart. *J. Clin. Med.* 6: 1–31.
54. Lyon, R.C., F. Zanella, J.H. Omens, and F. Sheikh. 2015. Mechanotransduction in cardiac hypertrophy and failure. *Circ. Res.* 116: 1462–1476.
55. Falet, H., A.Y. Pollitt, A.J. Begonja, S.E. Weber, D. Duerschmied, D.D. Wagner, S.P. Watson, and J.H. Hartwig. 2010. A novel interaction between FlnA and Syk regulates platelet ITAM-mediated receptor signaling and function. *J. Exp. Med.* 207: 1967–79.
56. Justa-schuch, D., M. Silva-garcia, E. Pilla, M. Engelke, F. Nakamura, H. Urlaub, and R. Geiss-friedlander. 2016. DPP9 is a novel component of the N-end rule pathway targeting the tyrosine kinase Syk. 8: 1–26.
57. Uzuki, B.Y.S. 2014. Review Emerging novel concept of chaperone therapies for protein

misfolding diseases. Proc. Jpn. Acad., Ser. B. 90: 145–162.

FIGURE LEGENDS

FIGURE 1. An overview of the structural organization of filamin A. (A) Schematic representation of FLNA dimer having 24 Ig-domains (gray) and the actin-binding domain (ABD) (yellow) in a monomer. The two monomers are dimerized via domain 24. Rod1 consists of domains 1–15, and rod2 consists of domains 16–23. The studied domains, 4–6, are colored in pale purple, pale green, and blue, respectively. The localization of *FLNA*-MVD P637Q mutation in domain 4 and V711D and H743P mutations in domain 5 have been highlighted with stars. The fourth missense mutation causing *FLNA*-MVD, G288R, is located in domain 1. (B) The crystal structure of FLNA3–5 (PDB ID 4M9P) (14) colored in pink (FLNA3), pale purple (FLNA4), and pale green (FLNA5). Residues V711 and H743, whose mutation to aspartic acid and proline residues, respectively, cause *FLNA*-MVD, are shown with ball-and-stick models.

Figure 2 FLNA-MVD causing mutations at FLNA5 destroyed the folding of both FLNA 5 and FLNA4. (A, B, C, D) The shape of the scattering curve (A) and Porod plot (C) of FLNA4–6 WT is typical for a folded protein, whereas the shape scattering curves (A) and Porod plots (C) of FLNA4–6 V711D and H743P show the mutant proteins were partially unfolded. The Kratky plot (B) further demonstrates that the FLNA4–6 WT is a multidomain protein with a flexible linker, while the mutated proteins are partially flexible. The distance distribution (P(r)) plot (D) reveals that the mutated proteins adopted significantly extended particle maximum dimensions, in contrast to the WT. The SAXS plots were prepared using merged scattering data (of 2 mg/ml and

4 mg/ml) from FLNA4–6 WT and the mutants in a single concentration (4 mg/ml). (*E, F, G*) Comparison of ^1H ^{15}N HSQC spectra of FLNA4–6 WT (*E*), V711D (*F*), and H743P (*G*) shows that both FLNA5 mutated fragments lack the FLNA5 (and most FLNA4) domain-specific NH cross peaks in the region typical for the structural protein, > 8.5 ^1H ppm. Instead, the vast majority of high-intensity cross peaks were clustered in the region between 7.7–8.5 ^1H ppm, indicating that both mutants had a high proportion of unfolded polypeptide chain. In contrast, the WT spectrum showed a well-dispersed correlation map spanning from 7 to 10 ^1H ppm, with more uniform intensities between the cross peaks. These data suggest that FLNA4–6 WT is comprised of three well-structured domains. The identity of the individual peaks in the mutant spectra (*F, G*) are shown, with FLNA4 peaks in green, FLNA5 peaks in red, and FLNA6 peaks in blue.

Figure 3 FLNA6 is not part the compact structure formed by FLNA3–5. (*A*) The plot of ^{15}N T_1 relaxation times versus the FLNA4–6 amino acid sequence clearly indicates that FLNA4–5 moves together but independently from FLNA6. Horizontal lines indicate the average values calculated for FLNA4–5 and FLNA6. (*B*) The limited protease digestion indicated that both FLNA5 mutations destabilized the FLNA4–6 structure, as after 10 min, no FLNA4–6 mutant proteins were left, while WT stayed intact even after 60 min of proteolysis treatment. (*C*) The WT FLNA3–5 (orange) and FLNA4–6 (gray) fragments have distinct experimental SAXS profiles. The merged data of 2 mg/ml and 4 mg/ml for both of the samples are presented. (*D*) The *ab initio* model of FLNA4–6 (surface presentation, grey, SASBDB ID SASDFD3) superimposed on the rigid body model of FLNA4–6 (with domain specific coloring: FLNA4 = purple, FLNA5 = green, and FLNA6 = blue) obtained by SASREF. The normalized spatial discrepancy (NSD) of

the alignment is 1.58. The χ^2 -value of the FLNA4–6 rigid body model against the experimental scattering data was 0.99 (estimated using CRY SOL) (42). (E) The *ab initio* model of FLNA3–5 (surface presentation = orange, SASBDB ID SASDEQ7) superimposed on the crystal structure of FLNA3–5 (PDB ID 4M9P, with domain-specific coloring: FLNA3 = pink, FLNA4 = purple, and FLNA5 = green). The NSD of the alignment was 1.49. The χ^2 -value of the FLNA3–5 crystal structure against the experimental scattering data was 1.0 (estimated using CRY SOL) (42), as previously reported in (20). (F) The rigid body models of FLNA4–6 obtained using CORAL (41) demonstrate the linker flexibility (spheres) and the movement of the FLNA6 domain in respect to the domain pair of FLNA4–5 (grey). The domain pair FLNA4–5 is superimposed on FLNA4–6, and only the two most distant orientations (blue and green) and one middle orientation (purple) of FLNA6 are shown out of the 50 calculated models. Superimposition of the presented CORAL models with the SASREF model gave NSD values of 1.49 (blue), 1.54 (purple), and 1.66 (green). The black arrows indicate the approximate movements of the blue and green models from the middle orientation in Ångströms, measured using V814 as the landmark between middle and the most distant orientations of FLNA6. The spheres representing the linker region between the FLNA4–5 domain pair and FLNA6 are dispersed, suggesting that the linker between the domains is mobile.

Figure 4 *FLNA*-MVD causing mutations at *FLNA5* abolished *PTPN12* binding to *FLNA*.

The *PTPN12* C-terminal fragment (600–700) binds to *FLNA4–6* WT with K_d 3.3×10^{-7} M (20), but binding to *FLNA4–6* V711D and H743P were hardly detected in SPR experiments.

